MyFinsight
Home
Blog
About
LB PHARMACEUTICALS INC (LBRX)
LB PHARMACEUTICALS INC (LBRX)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$37,559K
Free Cash flow
-$37,992K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Accounts payable and accrued exp...
Maturities of marketable securit...
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
General and administrative expen...
Purchase of marketable securitie...
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total research and development expenses
44,146
14,645
16,744
-
General and administrative expenses
9,769
7,459
13,660
-
Total operating loss
53,915
22,104
30,404
-
Non-operating income (loss)
2,312
3,050
5,200
-
Income tax provision
-
-
1
-
Net loss
-51,603
-19,054
-11,472
-13,733
Stock-based compensation expense
4,901
2,566
2,341
1,850
Shares issued for services rendered
-
-
0
0
Loss on write off of property and equipment
-
-
8
-
Write off of deferred offering costs
-
-
0
0
Depreciation and amortization
-
-
321
-
Depreciation
97
-154
-
236
Noncash lease expense
93
50
47
100
Realized gain on sale of marketable securities, net
0
0
0
119
Amortization (accretion) of premium (discounts) on investments, net
70
-17
-17
-244
Loss (gain) on change in fair value of derivative instruments
-662
200
-401
1,562
Prepaid expenses and other current assets
4,073
10,219
11,297
1,042
Operating lease liabilities
-57
-99
-98
-36
Accrued interest on marketable securities
-123
103
-100
-168
Accounts payable and accrued expenses
12,544
3,464
1,965
-2,875
Net cash used in operating activities
-37,629
-23,290
-18,103
-17,105
Purchases of property and equipment
363
32
40
12
Purchase of marketable securities
9,748
-
0
44,836
Proceeds from the sale of marketable securities
0
0
0
2,501
Maturities of marketable securities
10,200
0
0
2,500
Net cash (used in) provided by investing activities
89
-32
-40
-39,847
Proceeds from issuance of common stock and pre-funded warrants in a private placement
0
100,000
-
-
Proceeds from initial public offering
-
-
0
327,750
Payment of issuance costs for private placement
67
6,198
-
-
Payment of issuance costs for initial public offering
-
-
1,170
24,265
Proceeds from exercise of options
50
-
-
-
Proceeds from exercise of warrants
-2
29
0
247
Proceeds from issuance of redeemable convertible series c preferred stock
-
-
0
0
Payment of issuance costs for redeemable convertible series c preferred stock
-
-
0
0
Net cash provided by financing activities
-19
93,831
-1,170
303,732
Net increase (decrease) in cash, cash equivalents and restricted cash
-37,559
70,509
-19,313
246,780
Cash, cash equivalents and restricted cash, beginning of period
321,452
250,943
270,256
23,476
Cash, cash equivalents and restricted cash, end of period
283,893
321,452
250,943
270,256
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of marketable
securities
$10,200K
Net cash (used in)
provided by investing...
$89K
Canceled cashflow
$10,111K
Net increase
(decrease) in cash, cash...
-$37,559K
Canceled cashflow
$89K
Accounts payable and
accrued expenses
$12,544K
Stock-based compensation
expense
$4,901K
Loss (gain) on change
in fair value of...
-$662K
Depreciation
$97K
Noncash lease expense
$93K
Proceeds from exercise of
options
$50K
Purchase of marketable
securities
$9,748K
Purchases of property and
equipment
$363K
Net cash used in
operating activities
-$37,629K
Canceled cashflow
$18,297K
Net cash provided by
financing activities
-$19K
Non-operating income (loss)
$2,312K
Canceled cashflow
$50K
Net loss
-$51,603K
Canceled cashflow
$2,312K
Prepaid expenses and
other current assets
$4,073K
Accrued interest on
marketable securities
-$123K
Amortization (accretion) of
premium (discounts) on...
$70K
Operating lease
liabilities
-$57K
Payment of issuance
costs for private...
$67K
Proceeds from exercise of
warrants
-$2K
Total operating loss
$53,915K
Total research and
development expenses
$44,146K
General and
administrative expenses
$9,769K
Buy us a coffee